公开(公告)号：WO2004053052A2

公开(公告)日：2004-06-24

申请号：PCT/BR2003/000189

申请日：2003-12-08

Applicant: CAMARGO, Antônio ,  HAYASHI, Mirian ,  PORTARO, Fernanda ,  GUERREIRO, Juliano

Inventor： CAMARGO, Antônio ,  HAYASHI, Mirian ,  PORTARO, Fernanda ,  GUERREIRO, Juliano

IPC: C12N

CPC classification number: C12N9/6421

Abstract: This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions. It is also proposed the application of the inhibitors and competitors for the interaction of EOPA with ligands, including antibodies or their derivatives, for the treatment of tissular and neurodegenerative pathologies.

Abstract translation: 本发明涉及编码hEOPA多核苷酸的重组人内寡肽酶（hEOPA）多核苷酸，其允许在原核生物和真核生物（包括人）中表达EOPA; 使用合成底物来测定hEOPA的蛋白水解活性，或其伴侣活性或其作为可溶性肽受体的活性; 获得和使用其寡肽结合活性的特异性抗体和抑制剂作为激动剂，竞争剂和拮抗剂，其能够干扰其相互作用和与其它蛋白质的复合物形成。 本发明还涉及化学或遗传修饰的天然和重组蛋白质的应用，其目的是诊断和/或在中枢神经系统的先天性，感染性和退行性病理状况中的应用，以及精神和行为功能障碍。 还提出抑制剂和竞争剂在EOPA与配体（包括抗体或其衍生物）的相互作用中的应用用于治疗组织和神经退行性病变。

公开(公告)号：WO2008009085A1

公开(公告)日：2008-01-24

申请号：PCT/BR2007/000186

申请日：2007-07-19

Applicant: CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA ,  FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO-FAPESP ,  FERREIRA, Mônica ,  SILVA, Carla ,  PIMENTA, Daniel ,  PORTARO, Fernanda ,  CONCEIÇÃO, Kátia ,  DEMASI, Marilene

Inventor： FERREIRA, Mônica ,  SILVA, Carla ,  PIMENTA, Daniel ,  PORTARO, Fernanda ,  CONCEIÇÃO, Kátia ,  DEMASI, Marilene

IPC: C07K7/64

CPC classification number: C07K7/08

Abstract: The present invention refers to synthetic, cyclic peptides containing a sequence of 13 L-amino acids in their primary structure which present anti-inflammatory and antiallergic activities, useful for the treatment of acute or chronic inflammation and/or allergies, being particularly useful for the treatment of acute or chronic allergic asthma. The invention also describes a pharmaceutical composition containing said peptides, its use and a method to treat or prevent acute and/or chronic inflammatory and/or allergic disorders.

Abstract translation: 本发明涉及其主要结构中含有13个L-氨基酸序列的合成的环肽，它们具有抗炎和抗过敏活性，可用于治疗急性或慢性炎症和/或过敏，特别适用于 治疗急性或慢性过敏性哮喘。 本发明还描述了含有所述肽的药物组合物，其用途和治疗或预防急性和/或慢性炎性和/或过敏性疾病的方法。

公开(公告)号：WO2015081407A1

公开(公告)日：2015-06-11

申请号：PCT/BR2014/050025

申请日：2014-12-02

Applicant: FUNDAÇÃO BUTANTAN ,  TAMBOURGI, Denise Vilarinho ,  LOPES, Priscila Hess ,  MURAKAMI, Mario Tyago ,  PORTARO, Fernanda Calheta Vieira

Inventor： TAMBOURGI, Denise Vilarinho ,  LOPES, Priscila Hess ,  MURAKAMI, Mario Tyago ,  PORTARO, Fernanda Calheta Vieira

IPC: A61K31/18 ,  A61K31/404 ,  A61K31/44 ,  A61K31/34 ,  A61K31/35 ,  A61P43/00

CPC classification number: A61K31/443 ,  A61K31/404

Abstract: A presente invenção se refere, preferencialmente, ao uso do 4-bromo-N- [ (E) - (2-metil-lH-indol-3-il) metileneamino] benzenosulfonamida e do 4-metil-3-oxo-2- (3-piridilmetileno) benzo [3, 4-b] furan-6-il-4-clorobenzenossulfonato, (compostos 5 e 6, respectivamente), os quais são compostos capazes de inibir a ação tóxica da esfingomielinases D do veneno de Loxosceles, controlando o desenvolvimento do loxoscelismo cutâneo e sistémico; redução de hemólise, inibir a lesão cutânea, inibir a dermonecrose, inibir vias de sinalização intracelular e produção de espécies reativas de oxigénio. Além do potencial terapêutico, tais inibidores podem ser usados como ferramentas no estudo da ação de esfingomielinases e fosfolipases D. A presente invenção ainda se refere a uma composição farmacêutica para o tratamento de Loxoscelismo, redução de hemólise, inibir a lesão cutânea, inibir a dermonecrose, inibir vias de sinalização intracelular e produção de espécies reativas de oxigénio, a qual compreende os referidos compostos e um veiculo farmaceuticamente aceitável.

Abstract translation: 本发明优选地涉及4-溴-N - [（E） - （2-甲基-1H-吲哚-3-基）亚甲基氨基]苯磺酰胺和4-甲基-3-氧代-2-（3- 吡啶基亚甲基）苯并[3,4-b]呋喃-6-基-4-氯苯磺酸盐（分别为化合物5和6），它们是可以抑制来自软骨蛇毒的鞘磷脂酶D的毒性活性的化合物，控制皮肤和 全身性粘液病 减少溶血; 抑制皮肤病变的形成; 抑制皮肤坏死; 抑制细胞内信号通路和活性氧的产生。 除了其治疗潜力之外，所述抑制剂可用于研究鞘磷脂酶和磷脂酶D的活性。本发明还涉及用于治疗粘膜松解，减少溶血，抑制皮肤损伤形成，抑制皮肤坏死的药物组合物， 抑制细胞内信号传导途径和产生活性氧，其包含所述化合物和药学上可接受的载体。

公开(公告)号：WO2004053052A3

公开(公告)日：2006-08-03

申请号：PCT/BR0300189

申请日：2003-12-08

Applicant: CAMARGO ANTONIO ,  HAYASHI MIRIAN ,  PORTARO FERNANDA ,  GUERREIRO JULIANO

Inventor： CAMARGO ANTONIO ,  HAYASHI MIRIAN ,  PORTARO FERNANDA ,  GUERREIRO JULIANO

IPC: C12N9/64

CPC classification number: C12N9/6421

Abstract: This invention refers to a process for the determination of the primary structure of the mRNA coding for human endooligopeptidase A (hEOPA) and its protein sequence. In addition, the invention relates to a process for the determination of the structure of the hEOPA gene and the production of recombinant hEOPA. Furthermore, the invention relates to a process of generating antibodies against hEOPA in mice.

Abstract translation: 本发明涉及确定编码人内寡肽酶A（hEOPA）的mRNA及其蛋白质序列的一级结构的方法。 此外，本发明涉及确定hEOPA基因的结构和重组hEOPA的产生的方法。 此外，本发明涉及在小鼠中产生针对hEOPA的抗体的方法。

公开(公告)号：WO2002074782A3

公开(公告)日：2002-09-26

申请号：PCT/BR2002/000041

申请日：2002-03-18

Applicant: BIOLAB SANUS FARMACÊUTICA LTDA. ,  FUNDACÃO DE AMPARO À PESQUISA DO ESTADO DE SÂO PAULO - FAPESP ,  MARTINS DE CAMARGO, Antônio, Carlos ,  CALHETA VIEIRA PORTARO, Fernanda ,  FERRAGINI MURBACK, Alessandra ,  ALVES IANZER, Danielle ,  POLISELLI FARSKY, Sandra, Helena ,  PALMA, Mario, Sergio ,  HAYASHI, Mirian Akemi Furuie

Inventor： MARTINS DE CAMARGO, Antônio, Carlos ,  CALHETA VIEIRA PORTARO, Fernanda ,  FERRAGINI MURBACK, Alessandra ,  ALVES IANZER, Danielle ,  POLISELLI FARSKY, Sandra, Helena ,  PALMA, Mario, Sergio ,  HAYASHI, Mirian Akemi Furuie

IPC: A61K38/00 ,  C12N9/64

Abstract: The present invention patent refers to the isolation and purification of peptides secreted by serpent venom glands, specifically Bothrops jararaca ; to the peptide thus obtained, as well as to the production procedures by genetic engineering techniques in procaryotic and eukaryotic systems; to the engineered peptide thus obtained; to the production of said peptide by chemical synthesis, as well as to the peptide resulting from this chemical processing. It also refers to the utilization of said peptides, obtained by different procedures, in distinct pharmaceutical compositions, and introduced into the organism by a variety of means, in order for them to act as inhibitors of vasopeptidases, and consequently reduce systemic arterial blood pressure, and show local vasodilating action.